论文部分内容阅读
目的研究肝癌和肝硬变患者的肝炎病毒感染情况。方法用酶联免疫吸附测定（ＥＬＩＳＡ）法测定患者血清中的乙型肝炎病毒表面抗原（ＨＢｓＡｇ）、丙型肝炎病毒抗体（抗ＨＣＶ）和戊型肝炎病毒抗体（抗ＨＥＶ）。结果肝癌患者中抗ＨＥＶ阳性率为５８．９％（６３／１０７），ＨＢｓＡｇ阳性率为６９．２％（７４／１０７），抗ＨＣＶ阳性率为１０．３％（１１／１０７），肝硬变患者的阳性率依次为６３．０％（１７／２７）、７４．１％（２０／２７）、７．４％（２／２７）。只有抗ＨＥＶ阳性而ＨＢｓＡｇ和抗ＨＣＶ阴性的肝癌患者有１３例（１２．２％）。仅ＨＢｓＡｇ阳性而抗ＨＥＶ和抗ＨＣＶ阴性的有２４例（２２．４％），仅抗ＨＣＶ阳性而抗ＨＥＶ和ＨＢｓＡｇ阴性的有３例（２．８％）。全部阴性的有１０例（９．４％）。肝硬变患者中仅抗ＨＥＶ阳性而抗ＨＣＶ和ＨＢｓＡｇ阴性的有５例（１８．５％），仅ＨＢｓＡｇ阳性而抗ＨＥＶ和抗ＨＣＶ阴性的有９例（３３．３％），全部阴性的有１例（３．７％）。结论除ＨＢＶ和ＨＣＶ外，ＨＥＶ感染似乎在肝癌变及肝硬变中也起着一定的作用
Objective To investigate the hepatitis virus infection in patients with liver cancer and liver cirrhosis. Methods The serum of patients with hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) and hepatitis E virus antibody (anti-HEV) were determined by enzyme-linked immunosorbent assay (ELISA). Results The positive rate of anti-HEV in liver cancer patients was 58.9% (63/107), the positive rate of HBsAg was 69.2% (74/107), the positive rate of anti-HCV was 10.3% (11/107), cirrhosis The positive rates of patients were 63.0% (17/27), 74.1% (20/27), and 7.4% (2/27). Only anti-HEV positive HBsAg and anti-HCV negative HCC patients had 13 patients (12.2%). Only HBsAg-positive but anti-HEV and anti-HCV-negative were 24 cases (22.4%), and only 3 cases (2.8%) were anti-HCV positive and anti-HEV and HBsAg negative. All were negative in 10 cases (9.4%). Among the patients with cirrhosis, only 5 were positive for anti-HEV and negative for HCV and HBsAg (18.5%). Only 9 were positive for HBsAg positive but negative for anti-HEV and anti-HCV (33.3%). All were negative. There was 1 case (3.7%). Conclusion In addition to HBV and HCV, HEV infection seems to play a role in liver cancer and cirrhosis.